Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
RESEARCH TOOLSreports
4D Molecular Therapeutics (FDMT) Stock Price & Analysis
180 Followers
FDMT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.44 - $36.25
Previous Close$21.15
Volume245.89K
Average Volume (3M)545.38K
Market Cap
$1.09B
Enterprise Value$581.79M
Total Cash (Recent Filing)$525.91M
Total Debt (Recent Filing)$14.17M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 08, 2024EPS Estimate
-$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding51,703,412
10 Day Avg. Volume585,768
30 Day Avg. Volume545,375
Standard Deviation0.35
R-Squared0.16
Alpha-0.00336
Financial Highlights & Ratios
Price to Book (P/B)1.97
Price to Sales (P/S)57.23
Price to Cash Flow (P/CF)-10.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue28.45
Enterprise Value/Gross Profit28.07
Enterprise Value/Ebitda-6.38
Forecast
1Y Price Target
$57.83Price Target Upside173.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
4D Molecular Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe injection-free 4D-150 population has a superior OCT response compared to EYP-1901, which can ultimately drive improved 4D-150 long-term outcomes.
Commercial OpportunityThe wetAMD program addresses limitations of approved/investigational drugs and can potentially confer a >$5B commercial opportunity.
Regulatory OutlookA regulatory update on Phase 3 design for 4D-150 is planned, with initiation expected to drive investor confidence.
Bears Say
Clinical TrialsShares trading down ~10% as investor confidence in Phase 3 PoS and potential for accelerated approval will depend on upcoming clinical data.
Investor SentimentThe move -15% is more reflective of bearish investor positioning on ophthalmology gene therapy.
Product LaunchModel update pushes US/EU 4D-710 launch to 2027/2028, maintaining CF projections pending a larger subset of clinical data to evaluate commercial positioning.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $9.44 and its highest was $36.25 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
Currently, no data Available
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 32 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on May 09, 2024. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.741 by $0.081.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -$0.69.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 51,703,410 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.741. Following the earnings report the stock price went up 0.234%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Among the largest hedge funds holding 4D Molecular Therapeutics’s share is RA Capital Management. It holds 4D Molecular Therapeutics’s shares valued at 161M.
---
4D Molecular Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.83 (173.43% Upside)
$57.83 (173.43% Upside)
Hedge Fund Trend
Decreased
By 771.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
158.13%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.
---
FDMT Stock 12 Month Forecast
Average Price Target
$57.83
▲(173.43% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Editas Medicine
―
Best Analysts Covering FDMT
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+17.68%
reiterated a buy rating last month
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +17.68% per trade.
---